Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease

Richard L Doty, Matthew B Stern, Cheryl Pfeiffer, Steve M Gollomp, Howard I Hurtig
Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease

Richard L Doty, Matthew B Stern, Cheryl Pfeiffer, Steve M Gollomp, Howard I Hurtig

Abstract
Decreased olfactory function is among the first signs of idiopathic Parkinson's disease (PD). Whether such dysfunction is present to the same degree on both sides of the nose, however, is unknown. Furthermore, whether the deficit results from or is influenced by anti-Parkinsonian medications has not been definitely established. Odour identification ability was evaluated on the left and right sides of the nose in 20 early-stage untreated PD patients, 20 early-stage treated PD patients, and 20 controls. In all cases, the PD related olfactory dysfunction was bilateral and no difference was observed between the test scores of patients taking or not taking drugs for PD. Although asymmetries of unsystematic direction were present in the test scores of some PD patients, similar asymmetries were observed in the controls and the asymmetries were not related to the side of the major motor dysfunction. As in earlier work, no relation was present between the olfactory test scores and the degree of tremor, rigidity, bradykinesia, or gait disturbance at the time of testing. These findings indicate that the olfactory dysfunction of early stage PD is robust, typically of the same general magnitude on both sides of the nose, and uninfluenced by anti-Parkinsonian medications.

Decreased ability to smell is present in patients with early-stage Alzheimer's disease,1-3 idiopathic Parkinson's disease (PD),4-10 and the Parkinsonism-dementia complex of Guam (PDC).11 Although the physiological basis of these decrements is poorly understood, both peripheral and central segments of the olfactory pathways seem to be affected. For example, degenerative changes have been noted in the olfactory epithelium, the olfactory bulb, and the pyriform, prepyriform, and entorhinal cortices of patients with Alzheimer's disease.12-16 Although few studies of the neuropathology of the olfactory pathways of PD patients are available, near-total loss of cells within the anterior olfactory nucleus has been described for PDC.17

Recent studies suggest that the olfactory dysfunction of idiopathic PD does not progress significantly over time and is unrelated to the degree of motor and cognitive symptoms (implying independence from the more dynamic elements of the disease proper).18 Quantitative testing of only four untreated PD patients, however, has been reported in the literature,19 and whether the olfactory loss is symmetric or asymmetric is unknown as only bilateral testing has been performed (such testing largely reflects the best functioning nasal chamber).20 Given that the olfactory projections have a very large ipsilateral component (possibly explaining why unilateral temporal lobe resection impairs olfactory identification ability in the nostril ipsilateral to the resected lobe),21 the presence of olfactory asymmetry might provide a marker for hemispheric differences in neurotransmitter function. Functional or anatomical asymmetries of dopaminergic systems have been suggested, on the basis of both neuropsychological and neurochemical findings, to be present in the central nervous system (CNS) of PD patients, although the differences are often subtle.22-23

We studied whether the olfactory disorder of early-stage PD was asymmetric and, if so, whether the asymmetry was correlated with that observed in the motor system. We also compared the olfactory function of early-stage patients taking anti-Parkinsonian medications to that of early-stage patients not taking such medications.

Materials and methods
Subjects
The untreated study group comprised of 20 patients with early PD who were enrolled in the DATATOP clinical trial.24 All of them had never taken or had stopped taking anti-Parkinsonian medications for a period of at least six weeks before olfactory testing. Five were left handed and the remainder right handed. Twenty patients with PD not enrolled in DATATOP who were taking anti-Parkinsonian medications at the time of the study made up the medicated study group, whereas 20 individuals without neurological disease served as normal controls. One of the medicated PD patients was left handed; all of the others and the control subjects were right handed. The three groups were selected to contain patients of similar age, sex, and smoking habits, since these factors are known to influence the olfactory measure used in this study.25-26 Within the group taking antiparkinsonian drugs, 19 were
taking Sinemet (l-dopa with carbidopa), either alone (eight patients) or in combination with anticholinergic drugs (such as benztropine) or other dopamine-related drugs (such as amantadine, bromocriptine) or both (11 patients). One patient was taking an anticholinergic drug alone (ethopropazine). The two groups of patients were statistically comparable in terms of age, gender, and smoking habits (table 1). The duration of the disease, however, was much shorter in the untreated than in the treated patients (group \times gender analysis of covariance (ANCOVA) Group F (1,35) = 30.93, \ p < 0.001; covariate = age). The mean age of the control group was higher than that of the untreated PD group (\ t = 3.60, \ df = 19, \ p = 0.034), largely because four controls could not be placed within a five year age bracket to their respective PD matches. These differences were of no consequence to the findings of the study, as there was no association between disease duration and the magnitude of the olfactory dysfunction (in concurrence with earlier work), the direction of the age difference would mitigate against the hypothesis of a PD related deficit in olfactory function (which, in fact, was found); and age was used as a covariate in most of the statistical analyses.

**Assessment of cognitive function**

All of the PD patients were given the 40 item Picture Identification Test (PIT), a forced choice visual test identical to the UPSIT except that line drawings, rather than odours, are used as stimulus items. This test is specifically designed to screen for patients whose aberrant UPSIT scores might be due to problems in comprehending non-olfactory components of the test rather than to problems in olfactory perception. The PIT correlates well with a number of neuropsychological measures and is sensitive to dementia-related cognitive deficits, as described elsewhere.

**Assessment of neurological function**

Patients were staged according to the Hoehn and Yahr scale. The degree of tremor (left and right upper extremities), rigidity (left and right upper extremities), bradykinesia, and gait disturbance was rated on a standardised 4-point rating scale (0 = absent; 4 = severe) by neurologists with expertise in extrapyramidal disorders (MBS, HII, SMG). With the exception of a single stage III patient, all patients were either stage I (25) or stage II (14).

**Results**

Relative to normal controls, both the treated and untreated PD patients showed decreased olfactory function on both sides of the nose (table 2). Because several PD patients had severe olfactory dysfunction, data are presented separately in table 2 for those patients whose total UPSIT score (L + R) was greater than 20 to establish whether systematic decreases in the test scores for one or the other side of the nose might be confined to cases with a better sense of smell. No significant left:right differences in the test scores were found (regardless of disease stage or level of olfactory functioning), and the test scores were unrelated to the side of PD-related motor disturbance and not significantly influenced by the use of anti-Parkinsonian drugs (all p values > 0.10). No consistent relation was observed between the subjects' handedness and the asymmetry in the average test measures (for example, for right handed subjects the mean (SD) left and right UPSIT scores were 11.03 (4.40) and 10.56 (4.18); analogous scores for left-handers were 12.67 (3.98) and 11.33 (4.13)), although the small number of left handed subjects (six) precluded a definitive statistical test of this issue. As expected, however, on the basis of previous studies the PD patients exhibited clear olfactory dysfunction not attributable to non-olfactory related cognitive problems (that...
is, all but five scored 40/40 on the PIT; the remainder missed three or fewer items). Thus, the left and right side UPSIT scores of the controls were significantly higher than the left and right side UPSIT scores of the two patient groups (group x gender ANCOVA; covariate = age; group Fs (1, 55) = 7.69 & 9.51, p values = 0.008 and 0.003), which in no case differed significantly from one another (post hoc comparison p values > 0.20). Women, on average, obtained higher UPSIT scores than men, regardless of the side of nose tested (left and right UPSIT gender Fs (1, 55) = 5.55 and 3.86, p values = 0.022 and 0.054; mean (SD) left and right UPSIT scores for male and female PD patients and the male and female normal controls, respectively: 10.23 (4.03), 10.00 (4.16), 13.78 (4.35), 13.22 (4.68), 16.33 (2.99), 15.73 (3.28), 17.00 (3.00), and 17.60 (1.95). Analogous ANCOVAs between the untreated and treated PD groups yielded no significant group F values in any subject category (p > 0.10), although in most cases significant gender effects were observed (p values > 0.05).

Most of the PD patients showed UPSIT scores on each side of the nose that were equivalent or relatively close to one another. Thus, 15% had equivalent scores on each side of the nose, 30% had scores differing by one UPSIT point, and 20% had scores differing by two UPSIT points. Scores differing by three, four, five and six UPSIT points were noted in the remaining 12.5%, 12.5%, 5%, and 5% of the PD subjects, respectively. For the study group as a whole these differences were, on average, symmetrical (median (interquartile range) asymmetry value = 0 (−1 to +2.5)), where negative numbers indicate larger right side values and positive numbers larger left side values). This average lack of asymmetry was also observed for the normal subjects where the median asymmetry value was also equal to 0 (−3 to +2.5). No meaningful associations were observed between the direction of the asymmetries in the PD patients and the side of the major PD symptoms, even in those subjects who evidenced the largest apparent olfactory asymmetries.

Few of the correlations computed among the variables (for example, gender, age, smoking status, Hoehn and Yahr stage, neurological ratings) for the PD groups combined were significant at p = 0.05 (Bonferroni’s correction for inflated alpha). However, significant correlations were observed among the various olfactory measures (for example, left UPSIT v right UPSIT r = 0.81; dominant side UPSIT v nondominant side UPSIT r = 0.80) and among several neurological measures (for example, disease duration v right rigidity r = 0.48; gait v bradykinesia = 0.57; left rigidity v left tremor r = 0.60). The pattern of associations between the variables was similar to that observed in earlier studies, as shown by factor loadings extracted with a principal components factor analysis with a varimax rotation. Because of this similarity, the details of the factor analysis are not presented here.

As in our earlier work, each patient was asked whether he or she suffered from any smell or taste problems before olfactory testing. Four men and one woman within the untreated group and two men and two women within the treated group indicated that they had such problems (22.5%). Those aware of a smell problem before testing had lower UPSIT test scores than those who were unaware, also in accord with our earlier findings (respective means (SD): left side 8.44 (3.25) v 11.84 (11.23); right side 9.00 (2.65) v 11.23 (4.36); left plus right sides 17.44 (5.03) v 23.07 (8.42); respective ANCOVA (covariates gender and age) group F values (1, 35) = 5.40 (p = 0.03), 4.36 (p = 0.04), 5.51 (p = 0.03)).

Discussion

Our results show that the olfactory deficit observed in early PD is not secondary to the use of anti-Parkinsonian drugs and, for a given subject, is relatively similar on both sides of the nose. Although modest asymmetries were
present in the test scores of some of the PD patients, no relation was observed between the direction or magnitude of such asymmetries and the side of the motor dysfunction of hemi-Parkinsonism. Importantly, the median olfactory asymmetry value of the PD patients was zero and the range of asymmetry values fell within that observed for normal subjects. As in the case of several other disorders in which olfaction is impaired, 17 PD-related olfactory dysfunction was found to be less in women than in men. The basis of the olfactory dysfunction of PD is unknown, although it could reflect a PD-related vulnerability of the olfactory system to destruction by environmental factors or PD-related retrograde degenerative processes. Several theorists have proposed that some forms of Parkinsonism and other neurodegenerative disorders, such as Alzheimer's disease, may be caused by the entry of environmental agents or toxins from the nasal cavity into the brain. 18-20 The entry of viruses from the nasal cavity into the CNS is a well documented phenomenon. 21-24 and several large macromolecules can readily enter the CNS of rodents and other animals from the nose. 25-28 PD may be associated with a breakdown of the mucosal barrier which normally detoxifies xenobiotic agents and prevents them from damaging the olfactory membrane or from entering into the CNS via the olfactory receptors or surrounding mucosal tissue. 29-30 Germane to this notion are observations that nasal tissues contain very high concentrations of enzymes that metabolize xenobiotics (for example, cytochromes P-450, flavin containing monooxygenase and aldehyde dehydrogenases, and carboxylesterases). 31-34 Metabolic rates for xenobiotics within nasal tissue typically exceed those of other extrahepatic tissues and commonly exceed those of the liver; 35 36 and PD patients are less likely to detoxify drugs by sulphation or sulphoxidation than are similarly exposed controls. 37

Whatever the basis for the olfactory dysfunction in PD, our patients showed average total UPSIT scores (L plus R UPSIT values) which, for all practical purposes, were equivalent to the bilateral UPSIT scores of PD patients reported in earlier work (respective means (SD) 21.95 (8.05) v 20.83 (7.44)). 38 This is in spite of the fact that all but one of the present subjects were at Hoehn and Yahr stage I or stage II of the disease process (compared to about half the subjects in the earlier study) and that nearly all had Parkinsonian symptoms for a much shorter period of time (respective symptom duration means in years (SD) 5.0 (3.3) v 12.4 (10.1)). While these similarities are most likely a reflection of similar degrees of olfactory pathology within the two groups and the independence of the UPSIT scores from disease stage and duration, two factors may have had some differential influence on the test scores. Firstly, our patients were nearly five years younger than those in the earlier study (61.95 v 66.35 years) and UPSIT scores are known to decline several points over this age period. 39 Secondly, bilateral UPSIT testing, on average, tends to result in slightly higher UPSIT scores than unilateral testing (for example, the L plus R UPSIT score obtained from unilateral administration in eight PD subjects of the present study who had UPSIT scores > 18 was significantly lower than the bilateral UPSIT score obtained from these same individuals; respective means (SD) 26.63 (9.15) v 29.13, t = 3.50, p = 0.024). Presumably these effects offset one another to about the same degree.